Detection and correlation analysis of serum cytokines in non-small-cell lung cancer patients with bone and non-bone metastases

Figures & data

Table 1 Serum cytokine concentrations (pg/mL) in the two groups of non-small-cell lung cancer patients

Events	Bone metastasis (n=30)	Non-bone metastasis (n=30)	P-value
Cytokines and chemokines
SDF-1	31.32±68.14	9.77±0.00	0.343
Fractalkine	9.77±0.00	13.52±11.84	0.343
IP-10	1,975.97±1,090.68	1,452.32±1,006.17	0.279
MCP-1	401.78±285.93	526.64±749.59	0.629
IFNγ	261.43±303.80	40.85±62.62	0.075
IL-6	17.71±9.60	11.46±2.39	0.073
IL-10	22.63±22.55	15.13±10.71	0.355
IL-17α	71.41±67.29	81.47±130.91	0.831
IL-23	48.80±0.00	82.00±104.99	0.343
Growth factors
PDGF-αα	9,515.83±4,838.42	9,133.20±5,311.77	0.868
FGF	8.79±3.09	9.77±0.00	0.343
IGFBP-3	3,991.17±2,160.96	1,744.93±1,473.94	0.014*
VEGF	40.774±96.23	31.87±69.88	0.816

Notes: Data are presented as mean ± standard deviation.

* P<0.05 compared with the group with non-bone metastasis.

Abbreviations: VEGF, vascular endothelial growth factor; PDGF-αα, platelet-derived growth factor-αα; IP-10, interferon-inducible protein 10; MCP-1, monocyte chemotactic protein-1; IFNγ, interferon γ; IL, interleukin; IGFBP-3, insulin-like growth factor binding protein-3; SDF-1, stromal cell-derived factor-1; FGF, fibroblast growth factor.

Table 2 Correlations between IGFBP-3 concentration and other factors’ concentrations in serum in non-small-cell lung cancer patients with bone metastases (n=29)

	PDGF-αα	VEGF	IP-10	MCP-1	IFN	IL-6	IL-10	IL-17
IGFBP-3
r	0.322	0.804	0.026	0.785	0.151	0.239	0.251	0.287
P	0.399	0.009**	0.946	0.012*	0.699	0.536	0.514	0.455

Note:

* P<0.05,

** P<0.01 compared with r data.

Abbreviations: VEGF, vascular endothelial growth factor; PDGF-αα, platelet-derived growth factor-αα; IP-10, interferon-inducible protein 10; MCP-1, monocyte chemotactic protein-1; IFN, interferon; IL, interleukin; IGFBP-3, insulin-like growth factor binding protein-3.

Table 3 Correlations between IGFBP-3 concentration in serum and clinical features of non-small-cell lung cancer patients with bone metastases (n=29)

	Sex	Age	Pathology	T stage	N stage	PS score	Cancerous ostalgia in primary care	Number of metastatic bone lesions
IGFBP-3
r	−0.011	0.036	0.634	0.091	−0.136	0.670	0.701	0.324
P	0.978	0.926	0.067	0.816	0.728	0.048*	0.036*	0.434

Note:

* P<0.05 compared with r data.

Abbreviations: IGFBP-3, insulin-like growth factor binding protein-3; PS, performance status.